BioPharma Resources

Drug Trial Radar · NCT07074236

Pharmacokinetics and Pharmacodynamics Study

A Randomized, Open-label, Single-center, Parallel Study in Subjects With Normal or Elevated Low-density Lipoprotein Cholesterol Level to Compare the Pharmacokinetics and Pharmacodynamics of the Two Formulations of QLC7401 Injection

Last checked: Nov 19, 2026Latest source record: Jul 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Jul 2025

Primary completion

Jan 2026

Study completion Jan 2026

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the pharmacokinetics and pharmacodynamics behavior of the two formulation of QLC7401 injection to further evaluate the effect of the production site change.

Conditions

  • Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C

Interventions

  • QLC7401 injectionDrug

    QLC7401 injection is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA to inhibit the translation of PCSK9 and reduce expression of PCSK9 protein further to lower the level of LDL-C. QLC7401 injection was introduced by Qilu Pharmaceutical Co., Ltd. from Suzhou Ruibo Biotechnology Co., Ltd. QLC7401 injection was produced by Qilu Pharmaceutical Co., Ltd.

  • RBD7022 injectionDrug

    RBD7022 injection is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA to inhibit the translation of PCSK9 and reduce expression of PCSK9 protein further to lower the level of LDL-C. RBD7022 injection was produced by Suzhou Ruibo Biotechnology Co., Ltd.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose
  2. AUCTime frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose
  3. TmaxTime frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose
  4. t1/2Time frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose
  5. CL/FTime frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose
  6. VZ/FTime frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Affiliated Hospital of Qingdao University.

    Qingdao, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.